Less than 10% of individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it issues its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging broader and more equitable availability to these injectable treatments.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a lifelong illness that can be addressed with thorough and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to widespread availability to the injections that can aid individuals in losing considerable body mass, explains the body.
Weight-Loss Drug Scarcity
Even under the present best projected scenario, the production of such drugs could only cover approximately 100 million people – under 10% of eligible patients, per the WHO.
The recommendation encourages nations and manufacturers to widen availability, via strategies like voluntary licensing.
The intellectual property rights on semaglutide – the core component of a leading brand – is scheduled to end in several countries in 2026.
The Way Weight-Loss Jabs Operate
The injections mimick a body's own hormone to delay gastric emptying, curb appetite and enhance satiety so individuals reduce food intake.
Individuals usually start to lose weight in the initial weeks of starting on the weekly injections.
Studies suggests users may put most of the weight back on a year later of stopping the drug, as their typical food cravings return.
Being carrying excess weight increases your likelihood for contracting diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
